EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Krisztina M Papp-Wallace iD, Melissa D Barnes, Magdalena A Taracila, Christopher R Bethel, Joseph D Rutter, Elise T Zeiser, Katherine Young, Robert A Bonomo

Antibiotics · 11.05.2023 · 12 (5) · 892

DOI: 10.3390/antibiotics12050892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 11.05.2023. Verfasst von Krisztina M Papp-Wallace und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, Merck, Sharp & Dohme, Kenilworth, NJ USA, Cleveland Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime-avibactam.

Methods

The activity of imipenem-relebactam was assessed against a panel of 19 KPC-2 D179 variants. KPC-2 and the D179N and D179Y variants were purified for biochemical analyses. Molecular models were constructed with imipenem to assess differences in kinetic profiles.

Results

All strains were susceptible to imipenem–relebactam, but resistant to ceftazidime (19/19) and ceftazidime-avibactam (18/19). KPC-2 and the D179N variant hydrolyzed imipenem, but the D179N variant’s rate was much slower. The D179Y variant was unable to turnover imipenem. All three β-lactamases hydrolyzed ceftazidime at varying rates. The acylation rate of relebactam for the D179N variant was ~2.5× lower than KPC-2. Poor catalytic turnover by the D179Y variant precluded the determination of inhibitory kinetic parameters. Acyl-complexes with imipenem and ceftazidime were less prevalent with the D179N variant compared to the D179Y variant, supporting the kinetic observations that the D179Y variant was not as active as the D179N variant. Relebactam was slower to form an acyl-complex with the D179Y variant compared to avibactam. The D179Y model with imipenem revealed that the catalytic water molecule was shifted, and the carbonyl of imipenem was not within the oxyanion hole. Conversely in the D179N model, imipenem was oriented favorably for deacylation.

Conclusions

Imipenem–relebactam overcame the resistance of the D179 variants, suggesting that this combination will be active against clinical isolates harboring these derivatives of KPC-2.

Schlagwörter

Stichwörter der Autor:innen

KPC-2avibactambeta-lactambeta-lactamasecarbapenemaseceftazidimediazabicyclooctaneimipenemrelebactam

Autor:innen und Institutionen

  • Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.
  • Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
  • JMI Laboratories, a Subsidiary of Element Materials Technology, North Liberty, IA 52317, USA.
  • Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • GRECC, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.

ORCID-Profile: Krisztina M Papp-Wallace

Förderung

  • BLRD VA
  • Merck, Sharp & Dohme, Kenilworth, NJ USA
  • Cleveland Department of Veterans Affairs
  • Veterans Affairs Merit Review Program
  • Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center

Zitieren

APA

Papp-Wallace, K. M., Barnes, M. D., Taracila, M. A., Bethel, C. R., Rutter, J. D., Zeiser, E. T., Young, K., & Bonomo, R. A. (2023). The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase. Antibiotics, 12(5), 892. https://doi.org/10.3390/antibiotics12050892

Vancouver

Papp-Wallace KM, Barnes MD, Taracila MA, Bethel CR, Rutter JD, Zeiser ET, et al. The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase. Antibiotics. 2023;12(5):892. doi:10.3390/antibiotics12050892

BibTeX
@article{PappWallace2023,
  author = {Papp-Wallace, Krisztina M and Barnes, Melissa D and Taracila, Magdalena A and Bethel, Christopher R and Rutter, Joseph D and Zeiser, Elise T and Young, Katherine and Bonomo, Robert A},
  title = {The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase},
  journal = {Antibiotics},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {892},
  doi = {10.3390/antibiotics12050892}
}
Kostenlos starten →